Assignee
JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD
CN·8 granted patents·8 pending applications·9 citations·filing 2016–2025
Top patents by PatentIndex Score
16 records- 0190US12281177B2Heterodimer molecule based on CH3 domain, and preparation method and use thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2021·Granted Apr 22, 2025·1 cites·3 claims
- 0289US11396557B2Bispecific antibody or antibody mixture with common light chainsJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Jul 26, 2022·2 cites·8 claims
- 0387US11168149B2Heterodimer molecule based on CH3 domain, and preparation method and use thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Nov 9, 2021·3 cites·8 claims
- 0481US11634492B2Dimers and use thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2021·Granted Apr 25, 2023·1 cites·14 claims
- 0580US10808043B2Bispecific antibody or antibody mixture with common light chainsJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Oct 20, 2020·2 cites·2 claims
- 0673US2025257150A1Heterodimer molecule based on ch3 domain, and preparation method and use thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2025·Application pending·0 cites
- 0761US12281163B2Dimers and use thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Apr 22, 2025·0 cites·14 claims
- 0855US2024101707A1A method of preventing, alleviating or treating a tumorJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0954US2024307551A1Antibody-drug conjugate and application thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1053US2024382411A1Composition comprising pd-l1 antigen-binding fragment and use thereofJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1150US12448450B2Method for treating tumor using anti-CTLA4 single-domain antibodiesJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 21, 2025·0 cites·10 claims
- 1249US2023151116A1Efficacious dose for her2 bispecific antibodyJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 1349US2024141070A1Ox40/pd-l1 bispecific antibodyJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1446US12565531B2Bispecific fusion protein for tumor treatmentJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Mar 3, 2026·0 cites·12 claims
- 1545US2023017515A1COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENTJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1645US2023118053A1Combination of anti-her2 antibody and cdk inhibitior for tumor treatmentJIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →